Sec Form 3 Filing - Castelli Jeff @ AMICUS THERAPEUTICS, INC. - 2022-12-21

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Castelli Jeff 2. Issuer Name and Ticker or Trading Symbol AMICUS THERAPEUTICS, INC. [ FOLD] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Development Officer (Last) (First) (Middle) 3675 MARKET STREET 3. Date of Earliest Transaction (MM/DD/YY) 12/21/2022 (Street) PHILADELPHIA, PA19104 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 304,255( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Options (right to buy) $ 12.28 ( 2 ) 06/01/2025 Common Stock 50,000 D Stock Options (right to buy) $ 9.03 ( 2 ) 01/04/2026 Common Stock 50,000 D Stock Options (right to buy) $ 15.67 ( 2 ) 01/03/2028 Common Stock 39,762 D Stock Options (right to buy) $ 10.04 ( 3 ) 01/02/2029 Common Stock 82,644 D Stock Options (right to buy) $ 9.55 ( 4 ) 01/02/2030 Common Stock 107,575 D Stock Options (right to buy) $ 21.78 ( 5 ) 01/04/2031 Common Stock 46,396 D Stock Options (right to buy) $ 12.11 ( 6 ) 01/03/2032 Common Stock 108,266 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Castelli Jeff 3675 MARKET STREET PHILADELPHIA, PA19104 Chief Development Officer Signatures /s/ Christian Formica, Attorney-in-Fact 12/30/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes 161,910 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Amicus common stock. ( 2 )All of the options in this row are fully vested and exercisable as of December 21, 2022. ( 3 )The options reported in this row were granted on January 2, 2019 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 80,896 of such options were fully vested and exercisable and 1,748 remained unvested. ( 4 )The options reported in this row were granted on January 2, 2020 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 78,436 of such options were fully vested and exercisable and 29,139 remained unvested. ( 5 )The options reported in this row were granted on January 4, 2021 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 22,225 of such options were fully vested and exercisable and 24,171 remained unvested. ( 6 )The options reported in this row were granted on January 3, 2022 and will become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 0 of such options were fully vested and exercisable and 108,266 remained unvested.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.